INVESTOR RELATIONS
Advancing Antivirals to Address Global Infectious Diseases
We are a preclinical stage biopharmaceutical company dedicated to developing, and advancing novel antiviral therapies to address the unmet medical needs of patients affected by serious viral infections.
Viromme
We are a preclinical stage biopharmaceutical company dedicated to developing, and advancing novel antiviral therapies to address the unmet medical needs of patients affected by serious viral infections.
As a Model Medicines Endeavor (MME), we operate within a hub-and-spoke framework, leveraging the advanced AI-driven drug discovery platform developed at Model Medicines to deliver innovative solutions to global health challenges.
At the core of our scientific innovation is the discovery of RdRp Thumb-1, a cryptic, allosteric site conserved across RNA viruses. This groundbreaking target forms the basis of our lead candidate, MDL-001, an orally administered, broad-spectrum antiviral with demonstrated activity against diverse high-burden pathogens, including SARS-CoV-2, Influenza, Norovirus, and Hepatitis C.
With a focus on broad-spectrum antiviral solutions, our pipeline combines cutting-edge target discovery with the development of therapies designed to overcome the “one-virus, one-drug” paradigm. Our scientific platform also supports tailored drug discovery programs, enabling partnerships and custom solutions to address emerging infectious diseases. By combining new target discovery with robust therapeutic innovation, we are shaping the future of antiviral medicine.
Currently, we are advancing a portfolio of broad-spectrum antiviral therapies to deliver impactful solutions for RNA viruses, addressing both current pandemics and preparing for future viral threats. Our team is committed to improving health outcomes for billions of patients worldwide through scalable, accessible, and life-saving medicines.
Pre-Prints & Papers
